

GERPACYST- The Trial Protocol Of The Prospective, Multicenter, Interdisciplinary German Pancreas Club Cyst Registry

Kim Christin Honselmann¹, Jonathan Marschner¹, Anna Staufenbiel¹, Julia Bertram¹, Steffen
Deichmann¹, Carsten Engelke², Martha Kirstein², Jens Marquardt², Marko Damm³, Fanny
Borowitzka⁴, Veit Phillip⁵, Ilaria Pergolini⁶, Felix Harder⁷, Rickmer Braren⁷, Timo Gemoll¹,
Susanne Roth¹¹, Sebastian Krug¹⁵, Christoph W. Michalski¹¹, Robert Jaster⁴, Tobias Keck¹,
Ulrich Friedrich Wellner¹, and the GERPACYST Study Group^{8-10,12-14}

¹ Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, Germany,
Ratzeburger Allee 160, 23538 Lübeck, Germany

² Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Campus Luebeck

³ Department of Internal Medicine I, University Medical Center Halle, Germany

⁴ Department of Internal Medicine, University Medical Center Rostock, Germany

⁵ TUM School of Medicine and Health, Department of Clinical Medicine – Clinical Department for
Internal Medicine II, University Medical Center, Technical University of Munich, Munich, Germany

⁶ Department of Surgery, University Medical Center, Technical University of Munich, Munich, Germany

⁷ Department of Radiology, University Medical Center, Technical University of Munich, Munich,
Germany

⁸ Department of Surgery, Hospital Neustadt, Neustadt/Holstein, Germany

⁹ Section of Interdisciplinary Pancreatology, Department of Internal Medicine I, Ulm University
Hospital, Germany

¹⁰ Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, 89081 Ulm, Germany

¹¹ Department of Gastrointestinal & Infectious Diseases and Surgery, University Medical Center
Heidelberg, Germany

¹² Department of Surgery, University Hospital Ulm, Germany

¹³ Department of Internal Medicine I, University Medical Center Regensburg, Regensburg, Germany

¹⁴ Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical
Center Goettingen, Germany

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹⁵ Department of Gastroenterology, University Medical Center Heidelberg, Germany

31 Corresponding Author and Reprints:
32 Prof. Tobias Keck, Department Chair
33 Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck,
34 Ratzeburgerallee 160, 23538 Luebeck
35 Phone: 0451 500 40120, E-mail: Tobias.Keck@uksh.de
36
37 Parts of the study are currently funded by The Federal Ministry of Education and Research
38 (BMBF) (Funding number: 01KD2412A) and was supported by the Clinician-scientist school
39 Luebeck (project number 413535489) to KCH.
40
41 The study protocol has been presented at the annual meeting of the Digestive Disease Week
42 2024 and the German Society of Visceral Medicine 2023.
43
44 There are no conflicts to declare. Data is available from the first author KCH.
45
46 Revision chronology: Dec. 1st, 2023 Original
47 December 7th, 2023, 1st. Revision
48 December 12th, 2023 2nd Revision
49 January 11th, 2024 3rd Revision
50 August 13th, 2024 4th Revision

51

Abstract

52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89

Background

Cystic lesions of the pancreas have continued to present a clinical challenge for the past decades now. The increasing rate of detection, the lack of high-quality data on the natural biology of pancreatic cysts and the resulting difficulty to predict malignant transformation in different types of pancreatic cysts make patients with these diseases hard to manage. The German Pancreas Club Cyst Registry (GERPACYST) (DRKS00025927) establishes a platform to discover the natural entity specific biology of pancreatic cysts, in a multicenter manner that should allow to assess risk models for malignancy.

Method

This manuscript is written according to the SPIRIT guidelines. Ethical approval was obtained from the University of Luebeck (2024-265_1). In GERPACYST patients aged ≥ 18 years with a pancreatic cyst under surveillance or scheduled for surgery should be enrolled. Participating centers will complete an electronic Case Report Form (eCRF) via REDCap which is designed as a longitudinal study minimizing the input of repeated measures. Changes in patient baseline data, cyst characteristics, both endoscopic and imaging data will be entered typically every 6-12 months during patient follow-up. Biobanking will be performed, when available. Duration of observation per patient is up to a maximum of 20 years or until end of follow-up or death.

Discussion

GERPACYST will provide a valuable platform for clinical outcomes research. Fundamental factors affecting the development of pancreatic cysts over time will be identified. New research questions might be answered during the study period.

Trial registration

The study was prospectively registered at the German Clinical Trial Register (DRKS) under DRKS00025927 on September, 14th, 2021 before inclusion of the first patient. The Universal Trial Number (UTN) is U1111-1302-9822.

Trial sponsor

The study is sponsored by the German Pancreas Club (DPC) e.V. The sponsor has no role in study design, collection, management, interpretation or writing of the report. It is a mere supportive sponsoring.

Keywords:

Pancreatic cyst, Clinical registry, GerPaCyst, IPMN, SCN, SPPT, MCN

90 **GERPACYST Study Group**

- 91 Louisa Bolm ¹, Rüdiger Braun ¹, Rene Wilke ³, Fanny Borowitzka ⁴, Sebastian Rasch ⁵, Ihsan
92 Ekin Demir ⁶, Lukas Perkhofer ^{9,10}, Alexander Kleger ^{9,10}, Felix Huettner ¹², Philip Hildebrandt ^{8, 7},
93 Sophie Schlosser-Hupf ¹³, Martina Müller¹³, Christoph Ammer-Hermenau ¹⁴, Albrecht Neesse ¹

94 **Background**

95 Cystic lesions of the pancreas can either be neoplastic or non-neoplastic. Neoplastic cystic
96 lesions include intraductal mucinous papillary neoplasms (IPMN), mucinous cystic neoplasms
97 (MCN), serous cystic neoplasms (SCN) and solid pseudopapillary tumors (SPPT) and make
98 up 90% of all neoplastic cystic tumors of the pancreas (1). Depending on the entity, pancreatic
99 cysts bear malignant potential that is associated with outcomes comparable to pancreatic
100 cancer (2).

101 However, diagnostic accuracy remains limited (3). The accuracy of cross-sectional imaging
102 varies between 39.5% and 46%.

103 Pancreatic cysts occur in up to 45% in the German population (4). The incidence is roughly
104 13% in Germany and the management of pancreatic cysts has therefore become a highly
105 relevant clinical issue. Recent improvements in high-resolution imaging that make their
106 detection more frequent stands in contrast to treatment algorithms that remain highly
107 controversial in the absence of high- quality controlled studies. Between 2012 and 2018
108 international guidelines for the treatment of pancreas cysts were published (5-8). All these
109 guidelines make different recommendations on surveillance of small cysts after five years (9).
110 However, most of these recommendations are under the bias of retrospective surgical series
111 and observational studies (10, 11). Thus, they probably overestimate the potential for
112 malignancy. Analyses that go beyond five or even ten years hardly exist, which makes it
113 difficult to predict the biology of these entities (12). Furthermore, the knowledge about the long-
114 term risk of IPMN developing in pancreatic cancer is contradictory. Crippa et al. reported an
115 overall risk of 3,7% of IPMNs to develop into pancreatic cancer (13). Choi et al. reported that
116 a low risk IPMN (lesion without main pancreatic duct involvement or mural nodes) has a 7,8%
117 chance after 10 years to progress into pancreatic cancer and a high risk IPMN (mural nodes
118 and dilatated main pancreatic duct) has 25% chance after 10 years to progress into pancreatic
119 cancer (14).

120 In essence, the natural biologic history of most of the pancreatic cysts we treat today, is
121 unclear. Therefore, we aim to establish the GERPACYST registry, a prospective, 20-year

122 spanning, interdisciplinary, multicenter registry to structurally study the natural biology of
123 different pancreatic cysts over time in order to build multidimensional models to calculate the
124 individual's risk for the development of malignancy.

125

126

127

128 **Methods**

129 **Aims and scope of the registry study**

130 The registry was developed to provide a framework for studying the natural history of
131 pancreatic cystic lesions. The study idea was initially established at the German Pancreas
132 Club meeting 2020 and is endorsed and sponsored by the German Pancreas Club (DPC).
133 With regard to the above-mentioned aim, the following aspects were especially considered by
134 the founding team (KCH, JM, CWM, SK, RJ, PV, MD, TK, PV, SR and UFW). Relevant
135 outcomes and patient variables were chosen by the founding team. Definitions of the
136 International Study Group of Pancreatic Surgery (ISGPS), the TNM classification system, the
137 German S3 guideline for the treatment of pancreatic cancer and the Fukuoka guidelines were
138 utilized. The updated Kyoto guidelines were added August 13th, 2024.

139

140 **Study design**

141 The GERPACYST Study is a prospective, multicenter, interdisciplinary, longitudinal registry
142 study. A formal protocol detailing aims and regulations for data safety and publication has been
143 uploaded to <https://drks.de/search/en/trial/DRKS00025927> and can be accessed publicly. This
144 manuscript also provides a concise form to fulfill standards for documentation of registries and
145 follows the Standard protocol items: recommendations for clinical trials (SPIRIT) guidelines
146 (15).

147

148 **Registry organization**

149 The GERPACYST-registry is headed by the Steering Committee including KCH, MD, RJ, SK,
150 CM and UFW. The registry is physically located at the University of Luebeck, Germany.
151 Maintenance is secured by the IT-Service Center Luebeck.

152

153 **Participants, eligibility criteria and outcomes**

154 Patients presenting in the clinic of the participating centers including academic and academic-
155 affiliated hospitals currently all in Germany with a presumed or confirmed pancreatic cyst

156 (IPMN, MCN, SPPT, or SCN) and at minimum 18 years old will be evaluated to participate in
157 the study.

158 **Inclusion criteria:**

- 159 -presumed pancreatic cyst of the following entities (IPMN, MCN, SPPT, SCN)
- 160 - at least 18 years old

161 **Exclusion criteria:**

- 162 - Confirmed pseudocyst or diagnosis other than IPMN, MCN, SPPT, SCN
- 163 - Less than 18 years old

164

165 Suitable patients will be informed about the research project by the treating physician. The
166 written informed consent will be obtained by each patient. The treatment interventions will not
167 be altered by the study.

168 If the patient gives consent to participate in GERPACYST, data entry will occur at the time of
169 treatment initiation (surgery or start of non-surgical surveillance) and every 6-12 months after
170 treatment initiation for a period not to exceed 20 years.

171 Participating centers complete an electronic Case Report Form (eCRF). Study data is collected
172 and managed using REDCap electronic data capture tools hosted at the University of Luebeck,
173 Germany (16, 17) (Variables see Supplementary Table 1). Changes in patient characteristics
174 are entered during patient follow-up. In addition, patient biobank samples (blood, cyst fluid,
175 urine, tissue) will be stored upon availability.

176 The primary outcome of this trial is the development of high-grade dysplasia/invasive cancer
177 during follow-up or the absence of it. The secondary outcomes are death, quality of life
178 measured by EQ-5D-5L questionnaire, end-of-follow up and perioperative characteristics if
179 applicable such as complications, length of hospital stay, clavien-dindo classification.

180

181 **Initiation algorithm**

182 The study is still welcoming new participating centers from all over the world. Interested centers
183 can contact: kim.honselmann@uksh.de or redcap.lachi@uni-luebeck.de. Once the study

184 protocol has been reviewed by the ethics committee of the new center, and the contract has
185 been approved by both legal departments, the participating physicians will receive proper
186 training for patient inclusion in the REDCAP based database.

187

188 **Participant timelines and follow-up schedules**

189 Only after the patient has given written informed consent may the treating physician register
190 the patient in the database. After patient registration, mandatory baseline data on premedical
191 history, data on the disease, imaging and diagnostic modalities, treatment, and treatment
192 outcome (e.g., post-op complications) are documented. In addition, the date of treatment
193 initiation, patient number, and basic patient-specific information are documented (e.g., gender
194 or month and year of birth). The study's non-interventional design does not regulate modalities
195 or intervals between examinations and thus does not intervene in routine clinical practice.
196 Patients will be followed when presenting to the participating institutions or by telephone
197 interview every 6-12 months. A detailed patient schedule is shown in Figure 1.

198

199 **Patient rights and data safety**

200 Written informed consent for participation in the registry is obtained prior to inclusion at every
201 center from all patients. Patient data are entered and stored in pseudonymized form.
202 Institutional review boards have been obtained from every participating center. A data safety
203 manual can be obtained from the senior author (KCH). The GERPACYST platform was
204 initiated and enabled for data collection in pancreatic cysts in 2021 (Ethics Committee of the
205 University of Lübeck Az. 20-225 and 2024-265_1).

206

207 **Assessment of data**

208 After browser-based data entry, the data are automatically checked for completeness and
209 internal plausibility by software-based internal rules. Missing or implausible items create
210 warning messages. The data is usually entered after seeing the patient in the outpatient clinic

211 of the respective institution. Missing data will be handled according to the intended analysis.

212 There is currently no external monitoring for the GERPACYST Registry.

213

214 **Database structure**

215 GERPACYST is based on a web-based REDCAP data entry system for the systematic
216 collection of patient data, which was developed by Vanderbilt University (16). Data entry is
217 paperless and performed directly on-site at the respective medical facility (clinic/practice) via
218 an Internet browser. The REDCAP implementation meets all requirements of Good Clinical
219 Practice (ICH-GCP) as well as European data safety regulations. Corresponding certificates
220 for data security are available. The system is operated on a server of the computer center of
221 the University of Lübeck and is thus subject to strict access control. Data is collected in
222 pseudonymized form. Pseudonymization keys are kept separately from the database at the
223 participating institutions.

224 Duration of observation per patient is up to a maximum of 20 years or until the occurrence of
225 an event defined as end of follow-up or death. The study start was the fourth quarter of 2021
226 and is still ongoing. Centers are still initialized at the moment.

227

228 Entered variables include: baseline characteristics such as data on comorbidities like arterial
229 hypertension, diabetes mellitus, chronic obstructive lung disease, medical history of cancer,
230 family history and past medical history. Also, data on perioperative characteristics, if
231 applicable, will be collected. Imaging modalities on the most prominent cysts will be collected
232 at each follow-up. We will perform a quality-of-life questionnaire (EQ-5D-5L) at enrollment and
233 at end of follow-up or surgery (18). Cyst fluid analysis/molecular characteristics will be
234 collected, if available (Supplementary Table 1).

235

236 **Statistics**

237 The data required for the respective research question are compiled into an anonymized
238 project-specific evaluation data set with special consideration of the resulting re-identification

239 risk, if any, and made available for the research project. The GERPACYST study group
240 decides on the provision of the evaluation data sets for scientific evaluation.

241 For the development of risk models, we aim to utilize neuronal networks with elastic-net
242 regression using R. ROC-Curves will be built for candidate risk variables. According to our
243 and experience of others, sample size should be ten to 20 times higher than the number of
244 trainable parameters. As of now, we are planning to include 157 variables plus imaging and
245 biomarker profiles (about 40 different parameters). Our sample size should therefore be at
246 least 4000 patients (200x20). In order to achieve adequate participant enrolment, this study
247 was set up as a multicenter study internationally. Descriptive data will be evaluated with R or
248 SPSS according to the data characteristics. Nominal data will be evaluated with frequencies
249 and percentages and differences with Chi-square test or the Kaplan-Meyer methods if
250 pertaining to survival. Continuous data will be evaluated by median and interquartile range,
251 differences between two groups will be calculated by Mann-Whitney U Test. Kaplan-Meyer
252 approximation will be used for survival analyses. P-value will be set at $p < 0.05$.

253 The further exact analyses will be defined in a Statistical Analysis Plan (SAP) prior to the
254 corresponding evaluation. However, to ensure appropriate analyses, the nature of the data
255 must be considered. For this reason, descriptive analyses will be conducted, from which new
256 hypotheses and questions will arise. In particular, potential systematic biases must be
257 identified and accounted for in the analyses. Other important decisions include defining
258 subgroups of interest (e.g., patient groups that are usually excluded from RCTs) or pooling
259 similar therapies (e.g., when there are only a few patients in individual therapies) and dealing
260 with missing values in registry data. Some of the questions result in periodic evaluations. Other
261 questions arise due to the ongoing, observational process only in the course of the study,
262 which then result in supplementary SAPs. Answering questions that arise only in the course of
263 the study is one of the great advantages (and difficulties) of registry studies (19).

264 Only the ITSC of the University of Lübeck and the leaders of the GERPACYST study group or
265 persons appointed by the study group, such as staff of the Chir-NET office of the University
266 Hospital Schleswig-Holstein, have access to the complete data set.

267 The GerPaCyst registry has been established to be used together with the StuDoQIPancreas
268 Registry, if necessary and for facilitating data use and transfer within Germany, but also
269 internationally. Many items have been adapted from the StuDoQIPancreas registry,
270 accordingly (20).

271

272 **Declaration of interest**

273 None of the authors declare financial or competing interest for the overall trial and each study
274 site.

275

276 **Dissemination policy**

277 Trial results will be communicated with all participating centers on a regular basis including
278 half-yearly meeting sessions at the German Pancreas Club and the German Visceral Medicine
279 meetings (AG Pankreas DGVS). In addition, 4-monthly group meetings will be held virtually in
280 order to communicate possible protocol changes or interim-results. Publication will be decided
281 upon by the steering committee and author inclusion will be based on patient inclusion: up to
282 10 patients per year: 1 author from each center, 10 to 20 patients per year: 2 authors per
283 center, etc. Requests for data analysis of the whole cohort can be send to the steering
284 committee for evaluation. The full protocol has been uploaded to the german clinical trial
285 registry (www.drks.de). Participant-level dataset and statistical codes can be obtained from
286 KCH.

287

288 **Biological Specimens**

289 Blood samples or cyst (fluid) biopsies or surgical specimens will be collected at the
290 participating centers, if available and will possibly be used for genetic and molecular analysis
291 in ancillary studies in the future.

292

293 **Appendices**

294 Informed consent (Currently in German).

295 **Discussion**

296 More than twenty years after the first introduction of intraductal papillary mucinous neoplasms
297 (IPMN) by the World Health Organization (WHO), we still struggle to treat not only IPMNs, but
298 most pancreatic cysts. The increasing frequency of detection caused by the rising number of
299 radiology imaging exams will make this an even more pressing issue in the not so far future.

300 A large surgical series of 577 branch-duct IPMNs (BD-IPMN) found that at a median follow-up
301 of nearly seven years, almost 50% of BD-IPMNs progressed over time with 34% of patients
302 having either worrisome features or high-risk stigmata at the end of follow up (10). In contrast,
303 a radiologic group found no development of malignancy in a group of 49 patients with BD-
304 IPMNs less than 2 cm in diameter (21). Similarly, in an Asian study only 9% of 722 patients
305 developed malignancy over a five-year follow up-period (22). A recent large study from Verona
306 showed that the risk of developing malignancy in presumed BD-IPMN, that are stable over five
307 years and less than 30mm in size was comparable to that of the general population in the
308 same age group. They even proposed to discontinue surveillance in patients older than 75
309 years (23). However, the median follow-up was less than five years in this study. Furthermore,
310 the discrepancies between these studies might be attributed to the different sources of patients
311 (from surgery, radiology and gastroenterology separately).

312 Another point of discussion in the treatment of pancreatic cysts are main-duct IPMNs and the
313 questions if we should resect all of them, even in old and frail patients. Crippa et al. found that
314 the impact on survival was low, even in those IPMNs with a high malignancy rate (24).
315 Mucinous cystic neoplasms are to be resected, if they are larger than four centimeters (25).
316 But MCNs under four centimeters also had a malignancy rate of 43% in a retrospective study
317 by Hohn et al. (26). These recommendations are also based on retrospective surgical series,
318 which might overestimate the rate of malignancy.

319 Based on data of pancreatic cancer specimens, clonal evolution from the initiation of
320 tumorigenesis until the birth of the cell giving rise to the parental clone of primary cancer takes
321 an estimate of 11.7 years, an average of 6.8 years from then until the birth of the cell giving
322 rise to the index primary lesion, and an average of 2.7 years from then until the patients' death

323 (27). In total, the time of tumorigenesis, here in the example of pancreatic cancer, takes 20.2
324 years until metastatic dissemination and death. Maybe, we can assume that in the case of
325 pancreatic cysts, the timing is similar or even slower, illustrating the need for long-term follow-
326 up data.

327 The GERPACYST registry is therefore designed to include both patients treated by
328 gastroenterologists, radiologist and surgeons to reduce the bias of either surveillance or
329 resected patients. The web-based format and longitudinal study set up is supposed to facilitate
330 inclusion and follow-up and the duration of 20 years will hopefully give the opportunity to
331 include a large group of patients.

332 With artificial intelligence (AI) on the rise, GERPACYST will provide a well characterized cohort
333 to perform AI analyses with and to bring pancreatic cyst risk calculation to the next scientific
334 level.

335

336 **Conclusion**

337 We established a prospective, multicenter, interdisciplinary pancreatic cyst registry to enable
338 the uncovering of long-term pancreatic cyst biology and hope to contribute to improved patient
339 care in the future.

340

341

342

343

344 **Trial status**

345 10 university hospitals throughout Germany are currently participating in this study. The first
346 patient was entered in December 2021 and the study is ongoing. It is an interdisciplinary
347 cooperation of surgeons, radiologists and gastroenterologists. At least 5000 patients are
348 planned to be recruited from gastroenterology and surgical departments. Baseline
349 characteristics such as metabolic/endocrine diseases, risk factors and family history, as well
350 as pancreatic cyst data including MPD diameter, enhanced mural nodules, calcifications and
351 the quality of life EQ-5 questionnaire will be assessed during index visit and follow-up.
352 Biospecimens like blood, cyst fluid and cyst cytology will be collected, if needed.

353

354 **List of abbreviations**

355 IPMN (intraductal papillary-mucinous neoplasia)

356 MCN (mucinous-cystic neoplasia)

357 SCA (serous cystic adenoma)

358 SPN (solid pseudopapillary neoplasia) or SPPT (Solid pseudopapillary tumors)

359

360

361

362 **Declarations**

363 *Ethics approval and consent to participate*

364 Ethical approval was given by the University of Luebeck (Az. 20-225) on July 5th, 2020.

365 Patients are informed beforehand and give consent to participate in written form.

366 The authors declare no financial or other competing interests.

367

368 **Acknowledgements**

369 The study is registered at <https://drks.de/search/en/trial/DRKS00025927>. The protocol has
370 been reviewed and approved by the committees of each participating center. The study is
371 endorsed by the German Pancreas Club (DPC).

372 We thank the IT-Service Center University of Luebeck, especially Maike Wolf and Helge Illig
373 for the establishment and maintenance of the REDCAP Database.

374

375 **Author contributions**

376 KCH was the trial sponsor and PI. The study was designed by the founding team including
377 KCH, JM, CWM, SK, RJ, PV, MD, TK, PV, SR and UFW. UFW reviewed the statistics. All
378 authors edited the manuscript, and read and approved the final manuscript.

379

380

381

382

383

384

385

386 References

- 387 1. Farrell JJ. Pancreatic Cysts and Guidelines. *Dig Dis Sci*. 2017;62(7):1827-39.
- 388 2. Ciprani D, Weniger M, Qadan M, Hank T, Horick NK, Harrison JM, et al. Risk of
389 malignancy in small pancreatic cysts decreases over time. *Pancreatology*. 2020;20(6):1213-7.
- 390 3. Honselmann KC, Krauss T, Geserick S, Wellner UF, Wittel U, Hopt UT, et al. Cystic
391 lesions of the pancreas-is radical surgery really warranted? *Langenbecks Arch Surg*.
392 2016;401(4):449-56.
- 393 4. Kromrey ML, Bulow R, Hubner J, Paperlein C, Lerch MM, Ittermann T, et al.
394 Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of
395 pancreatic cysts in a population-based study. *Gut*. 2018;67(1):138-45.
- 396 5. Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al.
397 Revisions of international consensus Fukuoka guidelines for the management of IPMN of the
398 pancreas. *Pancreatology*. 2017;17(5):738-53.
- 399 6. Del Chiaro M, Verbeke C, Salvia R, Kloppel G, Werner J, McKay C, et al. European
400 experts consensus statement on cystic tumours of the pancreas. *Dig Liver Dis*. 2013;45(9):703-
401 11.
- 402 7. Vege SS, Ziring B, Jain R, Moayyedi P, Clinical Guidelines C, American
403 Gastroenterology A. American gastroenterological association institute guideline on the
404 diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology*.
405 2015;148(4):819-22; quiz e12-3.
- 406 8. Elta GH, Enestvedt BK, Sauer BG, Lennon AM. ACG Clinical Guideline: Diagnosis
407 and Management of Pancreatic Cysts. *Am J Gastroenterol*. 2018;113(4):464-79.
- 408 9. Muniraj T, Aslanian HR. Long-Term Follow-Up of Low-Risk Branch Duct IPMNs of
409 the Pancreas: Watch for Main Pancreatic Duct Dilatation, and for How Long? *Clin Transl*
410 *Gastroenterol*. 2018;9(10):198.
- 411 10. Pergolini I, Sahara K, Ferrone CR, Morales-Oyarvide V, Wolpin BM, Mucci LA, et al.
412 Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary
413 Mucinous Neoplasm in a Referral Center. *Gastroenterology*. 2017;153(5):1284-94 e1.
- 414 11. Han Y, Lee H, Kang JS, Kim JR, Kim HS, Lee JM, et al. Progression of Pancreatic
415 Branch Duct Intraductal Papillary Mucinous Neoplasm Associates With Cyst Size.
416 *Gastroenterology*. 2018;154(3):576-84.
- 417 12. Marchegiani G, Pollini T, Burelli A, Han Y, Jung HS, Kwon W, et al. Surveillance for
418 Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for
419 Discontinuation. *Gastroenterology*. 2023;165(4):1016-24 e5.
- 420 13. Crippa S, Capurso G, Camma C, Fave GD, Castillo CF, Falconi M. Risk of pancreatic
421 malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review
422 and meta-analysis. *Dig Liver Dis*. 2016;48(5):473-9.
- 423 14. Choi SH, Park SH, Kim KW, Lee JY, Lee SS. Progression of Unresected Intraductal
424 Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-
425 analysis. *Clin Gastroenterol Hepatol*. 2017;15(10):1509-20 e4.
- 426 15. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT
427 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*.
428 2013;346:e7586.
- 429 16. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
430 consortium: Building an international community of software platform partners. *J Biomed*
431 *Inform*. 2019;95:103208.
- 432 17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
433 data capture (REDCap)--a metadata-driven methodology and workflow process for providing
434 translational research informatics support. *J Biomed Inform*. 2009;42(2):377-81.
- 435 18. Foundation ER. EQ-5D-5L Amsterdam2024 [

- 436 19. Glicklich R, Dreyer, N., Leavy, M., eds. Registries for Evaluating Patient Outcomes: A
437 User's Guide: Agency for Healthcare Research and Quality; 2014.
- 438 20. Wellner UF, Klinger C, Lehmann K, Buhr H, Neugebauer E, Keck T. The pancreatic
439 surgery registry (StuDoQ|Pancreas) of the German Society for General and Visceral Surgery
440 (DGAV) - presentation and systematic quality evaluation. *Trials*. 2017;18(1):163.
- 441 21. Handrich SJ, Hough DM, Fletcher JG, Sarr MG. The natural history of the incidentally
442 discovered small simple pancreatic cyst: long-term follow-up and clinical implications. *AJR*
443 *Am J Roentgenol*. 2005;184(1):20-3.
- 444 22. Kwong WT, Hunt GC, Fehmi SM, Honerkamp-Smith G, Xu R, Lawson RD, et al. Low
445 Rates of Malignancy and Mortality in Asymptomatic Patients With Suspected Neoplastic
446 Pancreatic Cysts Beyond 5 Years of Surveillance. *Clin Gastroenterol Hepatol*. 2016;14(6):865-
447 71.
- 448 23. Marchegiani G, Pollini T, Burelli A, Han Y, Jung HS, Kwon W, et al. Surveillance for
449 Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for
450 Discontinuation. *Gastroenterology*. 2023.
- 451 24. Crippa S, Bassi C, Salvia R, Malleo G, Marchegiani G, Rebours V, et al. Low
452 progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk
453 stigmata undergoing non-operative management: a mid-term follow-up analysis. *Gut*.
454 2017;66(3):495-506.
- 455 25. Crippa S, Salvia R, Warshaw AL, Dominguez I, Bassi C, Falconi M, et al. Mucinous
456 cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients.
457 *Ann Surg*. 2008;247(4):571-9.
- 458 26. Hohn P, Soydemir MA, Luu AM, Janot-Matuschek M, Tannapfel A, Uhl W, et al. It's
459 not all about the size-characteristics and risk factors for malignancy of mucinous cystic
460 neoplasms of the pancreas. *Ann Transl Med*. 2020;8(23):1572.
- 461 27. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late
462 during the genetic evolution of pancreatic cancer. *Nature*. 2010;467(7319):1114-7.
- 463

Figure 1: SPIRIT schedule of enrollment, interventions, and assessment

TIMEPOINT**	STUDY PERIOD							
	Enrolment	Baseline	Follow-up					Close out
	-t ₁	0	t ₁	t ₂	t ₃	t ₄	etc.	t _x
ENROLMENT:								
Eligibility screen	X							
Informed consent	X							
<i>EQ-5D-5L</i>	X							x
Blood sample for biobanking		X	X	X	X	X	X	X
Standard-of-care:								
<i>Imaging</i>		x	x	x	x	x	x	
<i>Surgery</i>		?	?	?	?	?	?	
ASSESSMENTS:								
<i>Baseline variables (Age, sex, date of first visit)</i>		X	x	x	x	x	x	
<i>Comorbidities and symptoms</i>		x	%	%	%	%	%	%
<i>Cyst variables (Size, number, characteristics)</i>		x	X	X	X	X	x	X

% Update of any new comorbidities or symptoms that have developed during follow-up
 ?: Surgery might occur at baseline or during follow-up